Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

NRG / GY033

Trial Overview

Official Title

A PHASE II STUDY OF ANDROGEN RECEPTOR (AR) INHIBITION BY DAROLUTAMIDE IN COMBINATION WITH LEUPROLIDE ACETATE AND EXEMESTANE IN RECURRENT ADULT-TYPE OVARIAN GRANULOSA CELL TUMOR

Study Purpose

To test the effectiveness and the good and bad effects of the drug darolutamide in combination with leuprolide acetate and exemestane

 

Diagnosis

Recurrent adult-type granulosa cell tumors of the ovary

Eligibility

At least 1 prior treatment including an aromatase inhibitor

Intervention

All participants will receive darolutamide along with leuprolide acetate and exemestane

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT06169124?term=GY033&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Female
Age
19 and older
Enrollment Status
Suspended
Phase
Phase II
Methodist Health System Trial Code
GY033